

## DAFTAR PUSTAKA

1. World Health Organization. World Health Organization. 2019. HIV/TB. Available from: <https://www.who.int/news-room/fact-sheets/detail/hiv-tb>
2. World Health Organization. World Health Organization. 2021. Tuberculosis.
3. World Health Organization. World Health Organization. 2021 [cited 2024 Jan 14]. HIV/AIDS. Available from: <https://www.who.int/news-room/questions-and-answers/item/hiv-aids%0A%0A>
4. Kumar A, Revathi R, Sriram D, Curreli F, Debnath AK, Pai KS, et al. Targeting HIV-TB coinfection by developing novel piperidin-4-substituted imines: Design, synthesis, in vitro and in silico studies. *Arch Pharm (Weinheim)*. 2019;352(6):1–12.
5. Sharma SK, Mohan A, Kadiravan T. HIV-TB co-infection: Epidemiology, diagnosis & management. *Indian J Med Res*. 2005;121(4):550–67.
6. Kemenkes RI. Buku petunjuk TB-HIV untuk Petugas. Kementerian Kesehatan Republik Indonesia; 2016. 7 p.
7. World Health Organization. World Health Organization. 2022. TB Day 2022. Available from: <https://www.who.int/indonesia/news/campaign/tb-day-2022/fact-sheets>
8. Green C. TB dan HIV. Yogyakarta: Yayasan Spiritia; 2016.
9. Raesa FA. ANALISIS KETAHANAN HIDUP PASIEN KOINFEKSI TB-HIV DI RSUP M DJAMIL PADANG TAHUN 2016-2018 Oleh : Faradila Aninda Raesa Dosen Pembimbing 1 : Vivi Triana , SKM ., MPH Dosen Pembimbing 2 : Defriman Djafri , SKM ., MKM ., Ph . D Diajukan Sebagai Salah Satu Sya. Andalas University; 2020.
10. World Health Organization. Global Tuberculosis Report 2022. Geneva; 2023.
11. Dinas Kesehatan Provinsi Sumatera Barat. Laporan HIV-TB. Padang; 2023.
12. RSUP Dr. M. Djamil. Laporan Ranap B20.0 RSUP Dr. M. Djamil 2023. Padang; 2023.
13. Aung ZZ, Saw YM, Saw TN, Oo N, Aye HNN, Aung S, et al. Survival rate and mortality risk factors among TB–HIV co-infected patients at an HIV-specialist hospital in Myanmar: A 12-year retrospective follow-up study. *Int J Infect Dis* [Internet]. 2019;80:10–5. Available from: <https://doi.org/10.1016/j.ijid.2018.12.008>
14. World Health Organization. TB-HIV Fact Sheet: Asia and The Pacific. Geneva: World Health Organization; 2018.
15. Maemun S, Syarif S, Mahkota R. Gambaran Ketahanan Hidup (Kesintasan) Satu Tahun Pasien Koinfeksi TB-HIV Berdasarkan Waktu Awal Pengobatan Antiretroval (Arv) Pada Fase Lanjut Di Rumah Sakit Penyakit Infeksi (Rspi)

- Prof. Dr. Sulianti Saroso Periode Januari 2011-Mei 2014. *Indones J Infect Dis*. 2017;3(2):8–11.
16. Tancredi MV, Sakabe S, Waldman EA. Mortality and survival of tuberculosis coinfecting patients living with AIDS in São Paulo, Brazil: a 12-year cohort study. *BMC Infect Dis* [Internet]. 2022;22(1):1–13. Available from: <https://doi.org/10.1186/s12879-022-07232-6>
  17. Maruza M, Albuquerque MFPM, Braga MC, Barbosa MTS, Byington R, Coimbra I, et al. Survival of HIV-infected patients after starting tuberculosis treatment: A prospective cohort study. *Int J Tuberc Lung Dis*. 2012;16(5):618–24.
  18. Dantew B, Mengistie B, Alemayehu T. Survival and determinants of mortality in adult HIV/Aids patients initiating antiretroviral therapy in Somali Region, Eastern Ethiopia. *Pan Afr Med J*. 2015;22:1–8.
  19. Roshanaei G, Sabouri Ghannad M, Poorolajal J, Mohraz M, Molaiepoor L. Survival rates among co-infected patients with human immunodeficiency virus/tuberculosis in Tehran, Iran. *Iran J Public Health*. 2017;46(8):1123–31.
  20. Ismail I, Bulgiba A. Predictors of Death during Tuberculosis Treatment in TB/HIV Co-Infected Patients in Malaysia. *PLoS One*. 2013;8(8):1–7.
  21. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. *Lancet Glob Heal*. 2018;6(11):e1196–252.
  22. Mekuria LA, Sprangers MAG, Prins JM, Yalew AW, Nieuwkerk PT. Health-related quality of life of HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa. *AIDS Care* [Internet]. 2015;27(8):934–945. Available from: <https://doi.org/10.1080/09540121.2015.1020748>
  23. World Health Organization. WHO. 2023 [cited 2023 Mar 8]. HIV/AIDS. Available from: [https://www.who.int/health-topics/hiv-aids#tab=tab\\_1](https://www.who.int/health-topics/hiv-aids#tab=tab_1)
  24. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm reports Morb Mortal Wkly report Recomm reports*. 2006 Sep;55(RR-14):1–4.
  25. World Health Organization. Tuberculosis (TB) [Internet]. 2020. Available from: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>
  26. Centers of Diseases Control. Symptoms and Causes of Tuberculosis. [Internet]. 2021. Available from: <https://www.cdc.gov/tb/topic/basics/symptoms.htm>
  27. World Health Organization. Tuberculosis diagnostics. [Internet]. 2020. Available from: <https://www.who.int/tb/areas-of-work/laboratory/diagnostics/en>
  28. World Health Organization. Treatment of tuberculosis: guidelines. 2019.
  29. World Health Organization. Latent tuberculosis infection: updated and

- consolidated guidelines for programmatic management. [Internet]. 2018. Available from: <https://www.who.int/publications/i/item/9789241550239>
30. World Health Organization. World Health Organization. Geneva; 2019. Global Tuberculosis Report 2019. Available from: <https://www.who.int/publications/i/item/9789241565714>
  31. World Health Organization. Tuberculosis and HIV. 2018.
  32. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV co-infection. *PLoS Pathog*. 2012 Feb;8(2):e1002464.
  33. World Health Organization. Tuberculosis/HIV. 2012.
  34. World Health Organization. Global Tuberculosis Report 2020. Geneva; 2020.
  35. World Health Organization. Global Tuberculosis Report. 2023.
  36. Kemenkes RI. Petunjuk Teknis Kolaborasi HIV/TB: Tatalaksana dan PPI TBC HIV. 1. Kemenkes RI. Petunjuk Teknis Kolaborasi HIV/TB: Tatalaksana dan PPI TBC HIV. Jakarta: Kementerian Kesehatan Republik Indonesia; 2023., editor. Jakarta: Kementerian Kesehatan Republik Indonesia; 2023.
  37. Yanti MS. Hubungan Tingkat Self Efficacy dan Dukungan Sosial Teman Sebaya Dengan Penerimaan Diri Klien HIV Positif Di Puskesmas Dupak Surabaya. Skripsi Universitas Airlangga. Universitas Airlangga; 2017.
  38. Safitri A. PENGARUH DUKUNGAN KELUARGA TERHADAP KUALITAS HIDUP ORANG DENGAN HIV/AIDS (ODHA) DI PUSKESMAS JUMPANDANG BARU KOTA MAKASSAR. Universitas Islam Negeri Alauddin Makassar; 2022.
  39. Vyavaharkar M, Moneyham L, Tavakoli A, Phillips KD, Murdaugh C, Jackson K, et al. Social Support, Coping, and Medication Adherence Among HIV-Positive Women with Depression Living in Rural Areas of the Southeastern United States. *AIDS Patient Care STDS* [Internet]. 2007 Sep 1;21(9):667–80. Available from: <https://doi.org/10.1089/apc.2006.0131>
  40. Roshanaei G, Ghannad MS, Saatchi M, Khazaei S, Mirzaei M. Survival rates of human immunodeficiency virus and tuberculosis co-infected patients. *Jundishapur J Microbiol*. 2014;7(6).
  41. Lumu I, Musaazi J, Semeere A, Handel I, Castelnovo B. Survival and predictors of mortality after completion of TB treatment among people living with HIV: a 5-year analytical cohort. *BMC Infect Dis*. 2023;23(1):1–10.
  42. Atalell KA, Tebeje NB, Ekubagewargies DT. Survival and predictors of mortality among children co-infected with tuberculosis and human immunodeficiency virus at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. A retrospective follow-up study. *PLoS One*. 2018;13(5):1–12.
  43. Zhandybayeva A, Truzyan N, Shahumyan E, Kulzhabaeva A, Nugmanova Z, Denebayeva A, et al. The survival rate of tuberculosis patients in HIV-treated

- cohort of 2008-2018 in Almaty, Kazakhstan. *J Infect Dev Ctries.* 2020;14(11):116S-121S.
44. Ponnappan S, Ponnappan U. Aging and immune function: molecular mechanisms to interventions. *Antioxid Redox Signal.* 2011 Apr;14(8):1551–85.
  45. Kubjane M, Osman M, Boule A, Johnson LF. The impact of HIV and tuberculosis interventions on South African adult tuberculosis trends, 1990-2019: a mathematical modeling analysis. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis.* 2022 Sep;122:811–9.
  46. Harries AD, Kumar AM V, Satyanarayana S, Lin Y, Zachariah R, Lönnroth K, et al. Addressing diabetes mellitus as part of the strategy for ending TB. *Trans R Soc Trop Med Hyg.* 2016 Mar;110(3):173–9.
  47. Hussien S., Belachew T, Hussien N, Dessalegn M. Predictors of mortality among adult people living with HIV/AIDS on antiretroviral therapy at Suhul hospital, northeast Ethiopia. *BMC Res Notes.* 2019;12(1):1–6.
  48. Poulsen M., Sorensen J., Morch L., Kessing L. The influence of education and other socioeconomic factors on health and disease. *J Prev Med Hyg.* 2014;55(4):131–7.
  49. Birhan H, Derebe K, Muche S, Melese B. Statistical analysis on determinant factors associated with time to death of hiv/tb co-infected patients under haart at debre tabor referral hospital: An application of accelerated failure time-shared frailty models. *HIV/AIDS - Res Palliat Care.* 2021;13(July):775–87.
  50. Carrico AW, Hunt PW, Neilands TB, Dilworth SE, Martin JN, Deeks SG, et al. Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy. *J Acquir Immune Defic Syndr.* 2019 Jan;80(1):89–93.
  51. Lelisho ME, Wotale TW, Tareke SA, Alemu BD, Hassen SS, Yemane DM, et al. Survival rate and predictors of mortality among TB/HIV co-infected adult patients: retrospective cohort study. *Sci Rep [Internet].* 2022;12(1):1–11. Available from: <https://doi.org/10.1038/s41598-022-23316-4>
  52. Wondimu W, Dube L, Kabeta T. Factors affecting survival rates among adult tb/ hiv co-infected patients in mizan tepi university teaching hospital, south west ethiopia. *HIV/AIDS - Res Palliat Care.* 2020;12:157–64.
  53. Walker AS, Prendergast AJ, Mugenyi P, Munderi P, Hakim J, Kekitiinwa A, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. *Clin Infect Dis an Off Publ Infect Dis Soc Am.* 2012 Dec;55(12):1707–18.
  54. Muniyandi M, Rao V., Bhat J, Yadav R, Sharma R., Bhoneley M. Health system preparedness for multisystem infectious disease threats: a rapid qualitative study on the status quo in India. *BMJ Open.* 2019;9(11).
  55. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection . *N Engl J Med.* 2015;372(22):2127–35.
  56. Liu Z yin, Guo F ping, Han Y, Qiu Z feng, Zuo L yan, Li Y ling, et al. Impact

- of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study. *Chin Med J (Engl)*. 2009 Oct;122(20):2497–502.
57. Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science*. 1996 May;272(5265):1167–70.
  58. Deeks SG, Lewin SR, Havlir D V. The end of AIDS: HIV infection as a chronic disease. *Lancet (London, England)*. 2013 Nov;382(9903):1525–33.
  59. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. [Internet]. 2013. Available from: <https://www.who.int/publications/i/item/9789241505727>
  60. Sutherst RW. Global change and human vulnerability to vector-borne diseases. *Clin Microbiol Rev*. 2004 Jan;17(1):136–73.
  61. Drewnowski A, Rehm CD, Constant F. Water and beverage consumption among children age 4-13y in the United States: analyses of 2005–2010 NHANES data. *Nutr J* [Internet]. 2013;12(1):85. Available from: <https://doi.org/10.1186/1475-2891-12-85>
  62. Masaisa F, Gahutu JB, Mukiibi J, Delanghe J, Philippé J. Anemia in human immunodeficiency virus-infected and uninfected women in Rwanda. *Am J Trop Med Hyg*. 2011 Mar;84(3):456–60.
  63. Havlir D V, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med*. 2011 Oct;365(16):1482–91.
  64. Muyaya LM, Young T, Loveday M. Predictors of mortality in adults on treatment for human immunodeficiency virus-associated tuberculosis in Botswana: A retrospective cohort study. *Med (United States)*. 2018;97(16).
  65. Auld AF, Mbofana F, Shiraishi RW, Alfredo C, Sanchez M, Ellerbrock T V, et al. Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008. *PLoS One*. 2013;8(1):e54665.
  66. Kerschberger B, Hilderbrand K, Boulle AM, Coetzee D, Goemaere E, de Azevedo V, et al. The Effect of Complete Integration of HIV and TB Services on Time to Initiation of Antiretroviral Therapy: A Before-After Study. *PLoS One*. 2012;7(10).
  67. Yang N, He J, Li J, Zhong Y, Song Y, Chen C. Predictors of death among TB/HIV co-infected patients on tuberculosis treatment in Sichuan, China: A retrospective cohort study. *Med*. 2023;102(5):E32811.
  68. Kaplan R, Hermans S, Caldwell J, Jennings K, Bekker LG, Wood R. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. *BMC Infect Dis*. 2018;18(1):1–9.
  69. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune

- reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010 Apr;10(4):251–61.
70. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2014.
  71. da Silva Escada RO, Velasque L, Ribeiro SR, Cardoso SW, Marins LMS, Grinsztejn E, et al. Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil - associated factors and causes of death. *BMC Infect Dis.* 2017;17(1):1–10.
  72. Porto JP, Mantese OC, Arantes A, Freitas C, Gontijo Filho PP, Ribas RM. Nosocomial infections in a pediatric intensive care unit of a developing country: NHSN surveillance. *Rev Soc Bras Med Trop.* 2012;45(4):475–9.
  73. Pane I, Hadju VA, Aulia U, M L, Akbar H. DESAIN PENELITIAN MIXED METHOD. Yayasan Penerbit Muhammad Zaini; 2022.
  74. Teddlie C, Tashakkori A. *Foundations of Mixed Methods Research: Integrating Quantitative and Qualitative Approaches in the Social and Behavioral Sciences.* SAGE Publications Inc; 2009. 387 halaman.
  75. Liu B, Jayasundara D, Pye V, Dobbins T, Dore GJ, Matthews G, et al. Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia. *Lancet Reg Heal - West Pacific* [Internet]. 2021;12:100193. Available from: <https://doi.org/10.1016/j.lanwpc.2021.100193>
  76. Sudjana. *Metode Statistika.* Bandung: Tarsito; 2001.
  77. Ji YJ, Liang PP, Shen JY, Sun JJ, Yang JY, Chen J, et al. Risk factors affecting the mortality of HIV-infected patients with pulmonary tuberculosis in the cART era: A retrospective cohort study in China. *Infect Dis Poverty.* 2018;7(1):1–9.
  78. Puspitasari E, Yuniastuti E, Rengganis I, Rumende CM. Predictors of Mortality in Hospitalized HIV / AIDS Patients Prediktor Mortalitas Pasien HIV / AIDS Rawat Inap. *J Penyakit Dalam Indones.* 2016;3(1):22–8.
  79. Sujana SP. Analisis Ketahanan Hidup Pasien Coronavirus Disease 2019 (COVID-19) di RSUD Dr Achmad Mochtar Bukittinggi Tahun 2020. Universitas Andalas; 2021.
  80. Heriyanto H. Thematic Analysis sebagai Metode Menganalisa Data untuk Penelitian Kualitatif. *Anuva.* 2018;2(3):317.
  81. RSUP Dr. M. Djamil. LAKIP 2023.
  82. RSUP Dr. M. Djamil. Profil RSUP Dr. M. Djamil [Internet]. Available from: <https://rsdjamil.co.id/profil/tentang-kami/>
  83. Kegne TW, Anteneh ZA, Bayeh TL, Shiferaw BM, Tamiru DH. Survival Rate and Predictors of Mortality Among TB-HIV Co-Infected Patients During

- Tuberculosis Treatment at Public Health Facilities in Bahir Dar City, Northwest Ethiopia. *Infect Drug Resist.* 2024;17:1385–95.
84. Mekonnen D, Derbie A, Desalegn E. TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study. *BMC Res Notes.* 2015 Nov;8:666.
  85. Zeru MA. Prevalence and associated factors of HIV-TB co-infection among HIV patients: a retrospective Study. *Afr Health Sci.* 2021 Sep;21(3):1003–9.
  86. Musuenge BB, Poda GG, Chen PC. Nutritional Status of Patients with Tuberculosis and Associated Factors in the Health Centre Region of Burkina Faso. *Nutrients* [Internet]. 2020;12(9). Available from: <https://www.mdpi.com/2072-6643/12/9/2540>
  87. Mitku AA, Dessie ZG, Muluneh EK, Workie DL. Prevalence and associated factors of TB/HIV co-infection among HIV Infected patients in Amhara region, Ethiopia. *Afr Health Sci.* 2016 Jun;16(2):588–95.
  88. Stoica Călărășu C, Popa Miulescu AM, Turcu AA, Nitu FM. The Profile of the Patients with Double Infection HIV and TB in South West of Romania. *Curr Heal Sci J.* 2021;47(1):107–13.
  89. Yusmaniar Y, Kurniawan AH. Medication Adherence to Successful Tuberculosis Treatment Outcome among TB/HIV Patient at Prof. Dr. Sulianti Saroso Infectious Disease Hospital. *Pharmacol Clin Pharm Res.* 2020;5(3):98.
  90. Tshitenge S, Ogunbanjo GA, Citeya A. A mortality review of tuberculosis and HIV co-infected patients in Mahalapye, Botswana: Does cotrimoxazole preventive therapy and/or antiretroviral therapy protect against death? *African J Prim Heal care Fam Med.* 2018 Nov;10(1):e1–5.
  91. Roshanaei G, Ghannad MS, Saatchi M, Khazaei S, Mirzaei M. Survival rates of human immunodeficiency virus and tuberculosis co-infected patients. *Jundishapur J Microbiol.* 2014;7(6):1–10.
  92. Ferreira MD, Das Neves CP, De Souza AB, Beraldi-Magalhães F, Migliori GB, Kritski AL, et al. Predictors of mortality among intensive care unit patients coinfecting with tuberculosis and HIV. *J Bras Pneumol.* 2018;44(2):118–24.
  93. Kosgei RJ, Callens S, Gichangi P, Temmerman M, Kihara AB, David G, et al. Gender difference in mortality among pulmonary tuberculosis HIV co-infected adults aged 15-49 years in Kenya. *PLoS One.* 2020;15(12):e0243977.
  94. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. *AIDS.* 2008 Sep;22(14):1859–67.
  95. Roshanaei G, Ghannad MS, Saatchi M, Khazaei S, Mirzaei M. Survival rates of human immunodeficiency virus and tuberculosis co-infected patients. *Jundishapur J Microbiol.* 2014;7(6):1–5.

96. Fassin D, Schneider H. The politics of AIDS in South Africa: beyond the controversies. *BMJ*. 2003 Mar;326(7387):495–7.
97. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. *AIDS*. 2004 Apr;18(6):887–95.
98. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. *PLoS Med*. 2009 Jan;6(1):e11.
99. Grimsrud A, Lesosky M, Kalombo C, Bekker LG, Myer L. Implementation and Operational Research: Community-Based Adherence Clubs for the Management of Stable Antiretroviral Therapy Patients in Cape Town, South Africa: A Cohort Study. *JAIDS J Acquir Immune Defic Syndr* [Internet]. 2016;71(1). Available from: [https://journals.lww.com/jaids/fulltext/2016/01010/implementation\\_and\\_operational\\_research\\_.18.aspx](https://journals.lww.com/jaids/fulltext/2016/01010/implementation_and_operational_research_.18.aspx)
100. Ahmed A, Mekonnen D, Shiferaw AM, Belayneh F, Yenit MK. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study. *BMJ Open* [Internet]. 2018 Feb 1;8(2):e016961. Available from: <http://bmjopen.bmj.com/content/8/2/e016961.abstract>
101. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. *Int J Tuberc Lung Dis Off J Int Union against Tuberc Lung Dis*. 2004 Mar;8(3):286–98.
102. Saathoff E, Villamor E, Mugusi F, Bosch RJ, Urassa W, Fawzi WW. Anemia in adults with tuberculosis is associated with HIV and anthropometric status in Dar es Salaam, Tanzania. *Int J Tuberc Lung Dis Off J Int Union against Tuberc Lung Dis*. 2011 Jul;15(7):925–32.
103. Sime T, Oljira L, Diriba A, Firdisa G, Gezimu W. Effect of active tuberculosis on the survival of HIV-infected adult patients who initiated antiretroviral therapy at public hospitals of Eastern Ethiopia: A retrospective cohort study. *PLoS One* [Internet]. 2022;17(10 October):1–13. Available from: <http://dx.doi.org/10.1371/journal.pone.0277021>
104. Segal LN, Methé BA, Nolan A, Hoshino Y, Rom WN, Dawson R, et al. HIV-1 and bacterial pneumonia in the era of antiretroviral therapy. *Proc Am Thorac Soc*. 2011 Jun;8(3):282–7.
105. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. *Cochrane database Syst Rev*. 2010 Nov;2010(11):CD003940.
106. Ganiem AR, Dian S, Indriati A, Chaidir L, Wisaksana R, Sturm P, et al. Cerebral toxoplasmosis mimicking subacute meningitis in HIV-infected patients; a cohort study from Indonesia. *PLoS Negl Trop Dis*. 2013;7(1):e1994.



107. Vidal JE. HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease. *J Int Assoc Provid AIDS Care*. 2019;18:2325958219867315.
108. Naidoo K, Gengiah S, Yende-Zuma N, Mlobeli R, Ngozo J, Memela N, et al. Mortality in HIV and tuberculosis patients following implementation of integrated HIV-TB treatment: Results from an open-label cluster-randomized trial. *eClinicalMedicine* [Internet]. 2022;44:101298. Available from: <https://doi.org/10.1016/j.eclinm.2022.101298>
109. Weld ED, Solans BP, Salles I, Nonyane BAS, Sebe M, Beattie T, et al. Simultaneous initiation in ART-naïve PWH of DTG- based ART & 3HP maintains efficacious DTG levels. 2023.
110. Organization WH. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach [Internet]. 2006 rev. Geneva PP - Geneva: World Health Organization; Available from: <https://iris.who.int/handle/10665/43554>
111. Rothman JK, Greenland S, Lash T. *Modern Epidemiology*. 3rd ed. Philadelphia: LIPPINCOTT WILLIAMS & WILKINS; 2008.
112. Inamdar S, Kosambiya J, Modi A, Gohil A, Mehta A, Patel T. Age and Opportunistic Infections: Prevalence and Predictors among Older People Living With HIV. *Natl J Community Med*. 2018 Oct 17;9:8–2018.
113. Brown J, Lipman M. Community-Acquired Pneumonia in HIV-Infected Individuals. *Curr Infect Dis Rep*. 2014 Mar;16(3):397.
114. Low A, Gavriilidis G, Larke N, B-Lajoie MR, Drouin O, Stover J, et al. Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. *Clin Infect Dis* [Internet]. 2016 Jun 15;62(12):1595–603. Available from: <https://doi.org/10.1093/cid/ciw125>
115. Nariswari R. NILAI CD4 SEBAGAI PREDIKTOR TERJADINYA TOKSOPLASMOSIS SEREBRI PADA PASIEN HIV [Internet]. Universitas Gadjah Mada; 2020. Available from: <https://etd.repository.ugm.ac.id/penelitian/detail/199181>
116. Duggal S, Chugh T Das, Duggal AK. HIV and malnutrition: effects on immune system. *Clin Dev Immunol*. 2012;2012:784740.
117. Sow MS, Camara A, Sidibé S, Kaba I, Leno NN, Diallo BD, et al. Nutritional Status of Patients Co-Infected with TB/HIV During Tuberculosis Treatment at Conakry-Guinea UHC. *Open Infect Dis J*. 2021;13(1):11–7.
118. Refera H, Wencheke E. Survival of HIV-TB co-infected adult patients under ART in Ambo Referral Hospital, Ethiopia. *Ethiop J Heal Dev*. 2013;27(2):88–93.
119. Hsu HC, Huang PW, Cho YT, Chu CY. Cotrimoxazole as a Preventative Intervention for Pneumocystis Pneumonia in Pemphigus Patients Treated with Rituximab: A Retrospective Study. *Dermatol Ther (Heidelb)*. 2023

Jul;13(7):1561–76.

120. Graham SM. Cotrimoxazole prophylaxis for infants exposed to HIV infection. *Bull World Health Organ.* 2004;82(4):290–7.
121. Derseh NM, Agimas MC, Aragaw FM, Birhan TY, Nigatu SG, Alemayehu MA, et al. Incidence rate of mortality and its predictors among tuberculosis and human immunodeficiency virus coinfecting patients on antiretroviral therapy in Ethiopia: systematic review and meta-analysis. *Front Med.* 2024;11.
122. Kemenkes RI. Rencana Aksi Nasional Kolaborasi TB-HIV 2020-2024. 2021. 1 p.
123. Dhana A, Gupta RK, Hamada Y, Kengne AP, Kerkhoff AD, Yoon C, et al. Clinical utility of WHO-recommended screening tools and development and validation of novel clinical prediction models for pulmonary tuberculosis screening among outpatients living with HIV: an individual participant data meta-analysis. *Eur Respir Rev.* 2023;32(168).
124. World Health Organization. Tuberculosis & HIV. 2021.
125. Wijaya IMK. Infeksi Hiv ( Human Immunodeficiency Virus ) Pada Penderita Tuberkulosis. *Semin Nas FMIPA UNDIKSHA III.* 2013;3:295–303.
126. Cahyati WH, Muna N. Determinan Kejadian Tuberkulosis pada Orang dengan HIV/AIDS. *HIGEIA (Journal Public Heal Res Dev.* 2019;3(2):168–78.
127. Jha DK, Jha J, Jha AK, Achappa B, Holla R. Quality of life among HIV-tuberculosis co-infected patients. *Perspect Clin Res.* 2019;10(3):125–9.
128. Neves LA de S, Castrighini CDC, Reis RK, Rita S, Canini S, Gir E. Social support and quality of life of people with tuberculosis / HIV Suporte social e qualidade de vida de indivíduos com coinfeção tuberculose / HIV. *Rev Electron Trimest Enferm.* 2019;21–9.
129. Nabei JN, Bonful HA, Afari EA, Mohammed AG, Anum A. Predictors of quality of life of TB/HIV co-infected patients in the Northern region of Ghana. *BMC Infect Dis.* 2024 Apr;24(1):396.